Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 380


Clinical pharmacology in Stockholm 50 years-report from the jubilee symposium.

Eichelbaum M, Dahl ML, Sjöqvist F.

Eur J Clin Pharmacol. 2018 Jun;74(6):843-851. doi: 10.1007/s00228-018-2432-6. Epub 2018 Feb 27. No abstract available.


The formation of estrogen-like tamoxifen metabolites and their influence on enzyme activity and gene expression of ADME genes.

Johänning J, Kröner P, Thomas M, Zanger UM, Nörenberg A, Eichelbaum M, Schwab M, Brauch H, Schroth W, Mürdter TE.

Arch Toxicol. 2018 Mar;92(3):1099-1112. doi: 10.1007/s00204-017-2147-y. Epub 2017 Dec 28.


Improved Prediction of Endoxifen Metabolism by CYP2D6 Genotype in Breast Cancer Patients Treated with Tamoxifen.

Schroth W, Winter S, Mürdter T, Schaeffeler E, Eccles D, Eccles B, Chowbay B, Khor CC, Tfayli A, Zgheib NK, Eichelbaum M, Schwab M, Brauch H.

Front Pharmacol. 2017 Aug 24;8:582. doi: 10.3389/fphar.2017.00582. eCollection 2017.


CYP450 genotype and pharmacogenetic association studies: a critical appraisal.

Shah RR, Gaedigk A, LLerena A, Eichelbaum M, Stingl J, Smith RL.

Pharmacogenomics. 2016 Feb;17(3):259-75. doi: 10.2217/pgs.15.172. Epub 2016 Jan 18.


Highly sensitive simultaneous quantification of estrogenic tamoxifen metabolites and steroid hormones by LC-MS/MS.

Johänning J, Heinkele G, Precht JC, Brauch H, Eichelbaum M, Schwab M, Schroth W, Mürdter TE.

Anal Bioanal Chem. 2015 Sep;407(24):7497-502. doi: 10.1007/s00216-015-8907-8. Epub 2015 Jul 25.


Gastrointestinal absorption and metabolism of hesperetin-7-O-rutinoside and hesperetin-7-O-glucoside in healthy humans.

Actis-Goretta L, Dew TP, Lévèques A, Pereira-Caro G, Rein M, Teml A, Schäfer C, Hofmann U, Schwab M, Eichelbaum M, Crozier A, Williamson G.

Mol Nutr Food Res. 2015 Sep;59(9):1651-62. doi: 10.1002/mnfr.201500202. Epub 2015 Jun 23.


Direct imaging of octahedral distortion in a complex molybdenum vanadium mixed oxide.

Lunkenbein T, Girgsdies F, Wernbacher A, Noack J, Auffermann G, Yasuhara A, Klein-Hoffmann A, Ueda W, Eichelbaum M, Trunschke A, Schlögl R, Willinger MG.

Angew Chem Int Ed Engl. 2015 Jun 1;54(23):6828-31. doi: 10.1002/anie.201502236. Epub 2015 Apr 27.


The impact of steam on the electronic structure of the selective propane oxidation catalyst MoVTeNb oxide (orthorhombic M1 phase).

Heine C, Hävecker M, Trunschke A, Schlögl R, Eichelbaum M.

Phys Chem Chem Phys. 2015 Apr 14;17(14):8983-93. doi: 10.1039/c5cp00289c. Epub 2015 Mar 9.


The electronic factor in alkane oxidation catalysis.

Eichelbaum M, Hävecker M, Heine C, Wernbacher AM, Rosowski F, Trunschke A, Schlögl R.

Angew Chem Int Ed Engl. 2015 Mar 2;54(10):2922-6. doi: 10.1002/anie.201410632. Epub 2015 Jan 28.


Tamoxifen metabolism predicts drug concentrations and outcome in premenopausal patients with early breast cancer.

Saladores P, Mürdter T, Eccles D, Chowbay B, Zgheib NK, Winter S, Ganchev B, Eccles B, Gerty S, Tfayli A, Lim JS, Yap YS, Ng RC, Wong NS, Dent R, Habbal MZ, Schaeffeler E, Eichelbaum M, Schroth W, Schwab M, Brauch H.

Pharmacogenomics J. 2015 Feb;15(1):84-94. doi: 10.1038/tpj.2014.34. Epub 2014 Aug 5.


CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations.

Province MA, Goetz MP, Brauch H, Flockhart DA, Hebert JM, Whaley R, Suman VJ, Schroth W, Winter S, Zembutsu H, Mushiroda T, Newman WG, Lee MT, Ambrosone CB, Beckmann MW, Choi JY, Dieudonné AS, Fasching PA, Ferraldeschi R, Gong L, Haschke-Becher E, Howell A, Jordan LB, Hamann U, Kiyotani K, Krippl P, Lambrechts D, Latif A, Langsenlehner U, Lorizio W, Neven P, Nguyen AT, Park BW, Purdie CA, Quinlan P, Renner W, Schmidt M, Schwab M, Shin JG, Stingl JC, Wegman P, Wingren S, Wu AH, Ziv E, Zirpoli G, Thompson AM, Jordan VC, Nakamura Y, Altman RB, Ames MM, Weinshilboum RM, Eichelbaum M, Ingle JN, Klein TE; International Tamoxifen Pharmacogenomics Consortium.

Clin Pharmacol Ther. 2014 Feb;95(2):216-27. doi: 10.1038/clpt.2013.186. Epub 2013 Sep 23.


Reply to A.-S. Dieudonné et al and J.M. Rae et al.

Brauch H, Schroth W, Goetz MP, Mürdter TE, Winter S, Ingle JN, Schwab M, Eichelbaum M.

J Clin Oncol. 2013 Jul 20;31(21):2755-6. No abstract available.


Intestinal absorption, metabolism, and excretion of (-)-epicatechin in healthy humans assessed by using an intestinal perfusion technique.

Actis-Goretta L, Lévèques A, Rein M, Teml A, Schäfer C, Hofmann U, Li H, Schwab M, Eichelbaum M, Williamson G.

Am J Clin Nutr. 2013 Oct;98(4):924-33. doi: 10.3945/ajcn.113.065789. Epub 2013 Jul 17.


[Pharmacogenetics: current state after 30 years of research].

Eichelbaum M.

Dtsch Med Wochenschr. 2013 Mar;138(13):659-61. doi: 10.1055/s-0032-1332927. Epub 2013 Mar 19. Review. German. No abstract available.


Tamoxifen use in postmenopausal breast cancer: CYP2D6 matters.

Brauch H, Schroth W, Goetz MP, Mürdter TE, Winter S, Ingle JN, Schwab M, Eichelbaum M.

J Clin Oncol. 2013 Jan 10;31(2):176-80. doi: 10.1200/JCO.2012.44.6625. Epub 2012 Oct 22. No abstract available.


The intimate relationship between bulk electronic conductivity and selectivity in the catalytic oxidation of n-butane.

Eichelbaum M, Hävecker M, Heine C, Karpov A, Dobner CK, Rosowski F, Trunschke A, Schlögl R.

Angew Chem Int Ed Engl. 2012 Jun 18;51(25):6246-50. doi: 10.1002/anie.201201866. Epub 2012 May 8. No abstract available.


The microwave cavity perturbation technique for contact-free and in situ electrical conductivity measurements in catalysis and materials science.

Eichelbaum M, Stösser R, Karpov A, Dobner CK, Rosowski F, Trunschke A, Schlögl R.

Phys Chem Chem Phys. 2012 Jan 21;14(3):1302-12. doi: 10.1039/c1cp23462e. Epub 2011 Dec 7.


Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles.

Lucena MI, Molokhia M, Shen Y, Urban TJ, Aithal GP, Andrade RJ, Day CP, Ruiz-Cabello F, Donaldson PT, Stephens C, Pirmohamed M, Romero-Gomez M, Navarro JM, Fontana RJ, Miller M, Groome M, Bondon-Guitton E, Conforti A, Stricker BH, Carvajal A, Ibanez L, Yue QY, Eichelbaum M, Floratos A, Pe'er I, Daly MJ, Goldstein DB, Dillon JF, Nelson MR, Watkins PB, Daly AK; Spanish DILI Registry; EUDRAGENE; DILIN; DILIGEN; International SAEC.

Gastroenterology. 2011 Jul;141(1):338-47. doi: 10.1053/j.gastro.2011.04.001. Epub 2011 Apr 12.


Activity levels of tamoxifen metabolites at the estrogen receptor and the impact of genetic polymorphisms of phase I and II enzymes on their concentration levels in plasma.

Mürdter TE, Schroth W, Bacchus-Gerybadze L, Winter S, Heinkele G, Simon W, Fasching PA, Fehm T; German Tamoxifen and AI Clinicians Group, Eichelbaum M, Schwab M, Brauch H.

Clin Pharmacol Ther. 2011 May;89(5):708-17. doi: 10.1038/clpt.2011.27. Epub 2011 Mar 30. Erratum in: Clin Pharmacol Ther. 2012 Jun;91(6):1087.


X-ray-assisted formation of gold nanoparticles in soda lime silicate glass: suppressed Ostwald ripening.

Tatchev D, Hoell A, Eichelbaum M, Rademann K.

Phys Rev Lett. 2011 Feb 25;106(8):085702. Epub 2011 Feb 23.


Treatment of lung cancer patients and concomitant use of drugs interacting with cytochrome P450 isoenzymes.

Song X, Varker H, Eichelbaum M, Stopfer P, Shahidi M, Wilson K, Kaiser R, Finnern HW.

Lung Cancer. 2011 Oct;74(1):103-11. doi: 10.1016/j.lungcan.2011.01.016. Epub 2011 Mar 5.


Automated extraction of DNA and RNA from a single formalin-fixed paraffin-embedded tissue section for analysis of both single-nucleotide polymorphisms and mRNA expression.

Hennig G, Gehrmann M, Stropp U, Brauch H, Fritz P, Eichelbaum M, Schwab M, Schroth W.

Clin Chem. 2010 Dec;56(12):1845-53. doi: 10.1373/clinchem.2010.151233. Epub 2010 Oct 14.


The impact of thyroid disease on the regulation, expression, and function of ABCB1 (MDR1/P glycoprotein) and consequences for the disposition of digoxin.

Burk O, Brenner SS, Hofmann U, Tegude H, Igel S, Schwab M, Eichelbaum M, Alscher MD.

Clin Pharmacol Ther. 2010 Nov;88(5):685-94. doi: 10.1038/clpt.2010.176. Epub 2010 Sep 15.


Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS Clinical Trials Group study.

Ribaudo HJ, Liu H, Schwab M, Schaeffeler E, Eichelbaum M, Motsinger-Reif AA, Ritchie MD, Zanger UM, Acosta EP, Morse GD, Gulick RM, Robbins GK, Clifford D, Haas DW.

J Infect Dis. 2010 Sep 1;202(5):717-22. doi: 10.1086/655470.


CYP2D6 polymorphisms as predictors of outcome in breast cancer patients treated with tamoxifen: expanded polymorphism coverage improves risk stratification.

Schroth W, Hamann U, Fasching PA, Dauser S, Winter S, Eichelbaum M, Schwab M, Brauch H.

Clin Cancer Res. 2010 Sep 1;16(17):4468-77. doi: 10.1158/1078-0432.CCR-10-0478. Epub 2010 Jun 1.


Regulation of CYP3A4 by pregnane X receptor: The role of nuclear receptors competing for response element binding.

Istrate MA, Nussler AK, Eichelbaum M, Burk O.

Biochem Biophys Res Commun. 2010 Mar 19;393(4):688-93. doi: 10.1016/j.bbrc.2010.02.058. Epub 2010 Feb 18.


New feature: pathways and important genes from PharmGKB.

Eichelbaum M, Altman RB, Ratain M, Klein TE.

Pharmacogenet Genomics. 2009 Jun;19(6):403. No abstract available.


Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen.

Schroth W, Goetz MP, Hamann U, Fasching PA, Schmidt M, Winter S, Fritz P, Simon W, Suman VJ, Ames MM, Safgren SL, Kuffel MJ, Ulmer HU, Boländer J, Strick R, Beckmann MW, Koelbl H, Weinshilboum RM, Ingle JN, Eichelbaum M, Schwab M, Brauch H.

JAMA. 2009 Oct 7;302(13):1429-36. doi: 10.1001/jama.2009.1420.


Genetic influences on the pharmacokinetics of orally and intravenously administered digoxin as exhibited by monozygotic twins.

Birkenfeld AL, Jordan J, Hofmann U, Busjahn A, Franke G, Krüger N, Igel S, Mürdter T, Drescher S, Shi S, Engeli S, Schwab M, Eichelbaum M, Luft FC, Fromm MF.

Clin Pharmacol Ther. 2009 Dec;86(6):605-8. doi: 10.1038/clpt.2009.170. Epub 2009 Sep 23.


Pharmacogenomics of tamoxifen therapy.

Brauch H, Mürdter TE, Eichelbaum M, Schwab M.

Clin Chem. 2009 Oct;55(10):1770-82. doi: 10.1373/clinchem.2008.121756. Epub 2009 Jul 2. Review.


Thiopurine methyltransferase genetics is not a major risk factor for secondary malignant neoplasms after treatment of childhood acute lymphoblastic leukemia on Berlin-Frankfurt-Münster protocols.

Stanulla M, Schaeffeler E, Möricke A, Coulthard SA, Cario G, Schrauder A, Kaatsch P, Dördelmann M, Welte K, Zimmermann M, Reiter A, Eichelbaum M, Riehm H, Schrappe M, Schwab M.

Blood. 2009 Aug 13;114(7):1314-8. doi: 10.1182/blood-2008-12-193250. Epub 2009 Jun 17.


A polymorphism in the TC21 promoter associates with an unfavorable tamoxifen treatment outcome in breast cancer.

Rokavec M, Schroth W, Amaral SM, Fritz P, Antoniadou L, Glavac D, Simon W, Schwab M, Eichelbaum M, Brauch H.

Cancer Res. 2008 Dec 1;68(23):9799-808. doi: 10.1158/0008-5472.CAN-08-0247.


SERS and multiphoton-induced luminescence of gold micro- and nanostructures fabricated by NIR femtosecond-laser irradiation.

Eichelbaum M, Kneipp J, Schmidt BE, Panne U, Rademann K.

Chemphyschem. 2008 Oct 24;9(15):2163-7. doi: 10.1002/cphc.200800417. No abstract available.


Highly multiplexed genotyping of thiopurine s-methyltransferase variants using MALD-TOF mass spectrometry: reliable genotyping in different ethnic groups.

Schaeffeler E, Zanger UM, Eichelbaum M, Asante-Poku S, Shin JG, Schwab M.

Clin Chem. 2008 Oct;54(10):1637-47. doi: 10.1373/clinchem.2008.103457. Epub 2008 Aug 7.


Breast cancer risk reduction and membrane-bound catechol O-methyltransferase genetic polymorphisms.

Ji Y, Olson J, Zhang J, Hildebrandt M, Wang L, Ingle J, Fredericksen Z, Sellers T, Miller W, Dixon JM, Brauch H, Eichelbaum M, Justenhoven C, Hamann U, Ko Y, Brüning T, Chang-Claude J, Wang-Gohrke S, Schaid D, Weinshilboum R.

Cancer Res. 2008 Jul 15;68(14):5997-6005. doi: 10.1158/0008-5472.CAN-08-0043.


Photoluminescence of atomic gold and silver particles in soda-lime silicate glasses.

Eichelbaum M, Rademann K, Hoell A, Tatchev DM, Weigel W, Stößer R, Pacchioni G.

Nanotechnology. 2008 Apr 2;19(13):135701. doi: 10.1088/0957-4484/19/13/135701. Epub 2008 Feb 26.


Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group.

Schwab M, Zanger UM, Marx C, Schaeffeler E, Klein K, Dippon J, Kerb R, Blievernicht J, Fischer J, Hofmann U, Bokemeyer C, Eichelbaum M; German 5-FU Toxicity Study Group.

J Clin Oncol. 2008 May 1;26(13):2131-8. doi: 10.1200/JCO.2006.10.4182. Epub 2008 Feb 25.


Propafenone for the prevention of atrial tachyarrhythmias after cardiac surgery: a randomized, double-blind placebo-controlled trial.

Mörike K, Kivistö KT, Schaeffeler E, Jägle C, Igel S, Drescher S, Fux R, Marx C, Hofmann U, Engel C, Wagner F, Delabar U, Meisner C, Bail D, Böhm JO, Gleiter CH, Ziemer G, Rein JG, Hellberg KD, Eichelbaum M, Schwab M.

Clin Pharmacol Ther. 2008 Jul;84(1):104-10. doi: 10.1038/sj.clpt.6100473. Epub 2008 Jan 2.


Clinical Relevance of CYP2D6 Genetics for Tamoxifen Response in Breast Cancer.

Brauch H, Schroth W, Eichelbaum M, Schwab M, Harbeck N; in cooperation with the AGO TRAFO Comission.

Breast Care (Basel). 2008;3(1):43-50. Epub 2008 Feb 22.


Effects of rifampicin on global gene expression in human small intestine.

Oscarson M, Burk O, Winter S, Schwab M, Wolbold R, Dippon J, Eichelbaum M, Meyer UA.

Pharmacogenet Genomics. 2007 Nov;17(11):907-18.


TGFbeta2 and TbetaRII are valid molecular biomarkers for the antiproliferative effects of tamoxifen and tamoxifen metabolites in breast cancer cells.

Buck MB, Coller JK, Mürdter TE, Eichelbaum M, Knabbe C.

Breast Cancer Res Treat. 2008 Jan;107(1):15-24. Epub 2007 Feb 15.


Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes.

Schroth W, Antoniadou L, Fritz P, Schwab M, Muerdter T, Zanger UM, Simon W, Eichelbaum M, Brauch H.

J Clin Oncol. 2007 Nov 20;25(33):5187-93.


Increased absorption of digoxin from the human jejunum due to inhibition of intestinal transporter-mediated efflux.

Igel S, Drescher S, Mürdter T, Hofmann U, Heinkele G, Tegude H, Glaeser H, Brenner SS, Somogyi AA, Omari T, Schäfer C, Eichelbaum M, Fromm MF.

Clin Pharmacokinet. 2007;46(9):777-85.


When good drugs go bad.

Giacomini KM, Krauss RM, Roden DM, Eichelbaum M, Hayden MR, Nakamura Y.

Nature. 2007 Apr 26;446(7139):975-7. No abstract available.


A natural variant of the heme-binding signature (R441C) resulting in complete loss of function of CYP2D6.

Klein K, Tatzel S, Raimundo S, Saussele T, Hustert E, Pleiss J, Eichelbaum M, Zanger UM.

Drug Metab Dispos. 2007 Aug;35(8):1247-50. Epub 2007 Apr 25.


Variability in human hepatic MRP4 expression: influence of cholestasis and genotype.

Gradhand U, Lang T, Schaeffeler E, Glaeser H, Tegude H, Klein K, Fritz P, Jedlitschky G, Kroemer HK, Bachmakov I, Anwald B, Kerb R, Zanger UM, Eichelbaum M, Schwab M, Fromm MF.

Pharmacogenomics J. 2008 Feb;8(1):42-52. Epub 2007 Apr 3.


Selective induction of human hepatic cytochromes P450 2B6 and 3A4 by metamizole.

Saussele T, Burk O, Blievernicht JK, Klein K, Nussler A, Nussler N, Hengstler JG, Eichelbaum M, Schwab M, Zanger UM.

Clin Pharmacol Ther. 2007 Sep;82(3):265-74. Epub 2007 Mar 7.


Molecular mechanism of basal CYP3A4 regulation by hepatocyte nuclear factor 4alpha: evidence for direct regulation in the intestine.

Tegude H, Schnabel A, Zanger UM, Klein K, Eichelbaum M, Burk O.

Drug Metab Dispos. 2007 Jun;35(6):946-54. Epub 2007 Mar 7.


Functional analysis of the polymorphism -211C>T in the regulatory region of the human ABCC3 gene.

Gradhand U, Tegude H, Burk O, Eichelbaum M, Fromm MF, König J.

Life Sci. 2007 Mar 27;80(16):1490-4. Epub 2007 Jan 20.


Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals.

Rotger M, Tegude H, Colombo S, Cavassini M, Furrer H, Décosterd L, Blievernicht J, Saussele T, Günthard HF, Schwab M, Eichelbaum M, Telenti A, Zanger UM.

Clin Pharmacol Ther. 2007 Apr;81(4):557-66. Epub 2007 Jan 18.


Supplemental Content

Loading ...
Support Center